LRRK2 kinase inhibitor (GSK) treatment abolished Drp1 increase and TNF-α release induced by LPS treatment. BV2 (A) and primary rat microglia (G) cells were treated as described in
. Analysis and a representative of three Western blot images are shown. Effectiveness of GSK treatment was confirmed by decrease in LRRK2 pS935 autophosphorylation level (pS935/total LRRK2, B &H). Relative densitometric analyses of Drp1 (C & I) or Tom20 (D & J), normalized by β-actin, and Drp1/Tom20 (E & K) levels in BV2 (C~E) and primary rat microglia (H~L) cells are shown. The secretion of TNF-α by murine BV2 cells (F) and rat primary microglia (L) was measured by ELISA. The statistical analysis was performed by ANOVA with Bonferroni post-hoc test. *
p<0.0001, n.s., not significant.